Not exact matches
«T - cell receptor therapy
achieves encouraging clinical responses in multiple
myeloma: NY - ESO T cell receptor therapy found to be safe, with no cytokine release syndrome cases.»
Nearly 80 % of R / R
myeloma patients with severe renal impairment requiring hemodialysis
achieved disease control with this treatment combination.
Instead, newer trials have suggested that the use of minimal residual disease (MRD) status may be a valid surrogate outcomes for survival in patients with
myeloma who
achieved CR.
sorafenib induces cell death in human
myeloma cell lines in a laboratory environment by preventing a certain kind of protein - level activity, an effect that also was
achieved when the
myeloma cells had developed a resistance to